Selected research
Industry Research
Pulmonary Hypertension Drug Industry Research Report 2026
Market perspective
The global Pulmonary Hypertension Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Pulmonary Hypertension Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Pulmonary Hypertension Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Pulmonary Hypertension Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Pulmonary Hypertension Drug include Biolab Sanus Farmaceutica Ltda., Hanmi Pharmaceuticals, Co. Ltd., Ikaria Inc., Proreo Pharma AG, Vectura Group plc, Vicore Pharma AB, Bayer AG and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Pulmonary Hypertension Drug market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Pulmonary Hypertension Drug Market by Company
Biolab Sanus Farmaceutica Ltda.
Hanmi Pharmaceuticals, Co. Ltd.
Ikaria Inc.
Proreo Pharma AG
Vectura Group plc
Vicore Pharma AB
Bayer AG
Sanofi
Pulmonary Hypertension Drug Segment by Type
IK-3001
Riociguat
Sildenafil Citrate IMD
SAR-407899
IK-7002
Others
Pulmonary Hypertension Drug Segment by Application
Clinic
Hospital
Others
Pulmonary Hypertension Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Hypertension Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Hypertension Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Hypertension Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Pulmonary Hypertension Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Pulmonary Hypertension Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Pulmonary Hypertension Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- IK-3001
- Riociguat
- Sildenafil Citrate IMD
- SAR-407899
- IK-7002
- Others
Applications
- Clinic
- Hospital
- Others
Companies covered
- Biolab Sanus Farmaceutica Ltda.
- Hanmi Pharmaceuticals, Co. Ltd.
- Ikaria Inc.
- Proreo Pharma AG
- Vectura Group plc
- Vicore Pharma AB
- Bayer AG
- Sanofi
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Pulmonary Hypertension Drug Market Size (2021-2032)
- 2.2.2 Global Pulmonary Hypertension Drug Sales (2021-2032)
- 2.2.3 Global Pulmonary Hypertension Drug Market Average Price (2021-2032)
- 2.3 Pulmonary Hypertension Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 IK-3001
- 2.3.3 Riociguat
- 2.3.4 Sildenafil Citrate IMD
- 2.3.5 SAR-407899
- 2.3.6 IK-7002
- 2.3.7 Others
- 2.4 Pulmonary Hypertension Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinic
- 2.4.3 Hospital
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Pulmonary Hypertension Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Pulmonary Hypertension Drug Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Pulmonary Hypertension Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Pulmonary Hypertension Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Pulmonary Hypertension Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Pulmonary Hypertension Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Pulmonary Hypertension Drug, Product Type & Application
- 3.8 Global Manufacturers of Pulmonary Hypertension Drug, Established Date
- 3.9 Global Pulmonary Hypertension Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Biolab Sanus Farmaceutica Ltda.
- 4.1.1 Biolab Sanus Farmaceutica Ltda. Company Information
- 4.1.2 Biolab Sanus Farmaceutica Ltda. Business Overview
- 4.1.3 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Product Portfolio
- 4.1.5 Biolab Sanus Farmaceutica Ltda. Recent Developments
- 4.2 Hanmi Pharmaceuticals, Co. Ltd.
- 4.2.1 Hanmi Pharmaceuticals, Co. Ltd. Company Information
- 4.2.2 Hanmi Pharmaceuticals, Co. Ltd. Business Overview
- 4.2.3 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Product Portfolio
- 4.2.5 Hanmi Pharmaceuticals, Co. Ltd. Recent Developments
- 4.3 Ikaria Inc.
- 4.3.1 Ikaria Inc. Company Information
- 4.3.2 Ikaria Inc. Business Overview
- 4.3.3 Ikaria Inc. Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Ikaria Inc. Pulmonary Hypertension Drug Product Portfolio
- 4.3.5 Ikaria Inc. Recent Developments
- 4.4 Proreo Pharma AG
- 4.4.1 Proreo Pharma AG Company Information
- 4.4.2 Proreo Pharma AG Business Overview
- 4.4.3 Proreo Pharma AG Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Proreo Pharma AG Pulmonary Hypertension Drug Product Portfolio
- 4.4.5 Proreo Pharma AG Recent Developments
- 4.5 Vectura Group plc
- 4.5.1 Vectura Group plc Company Information
- 4.5.2 Vectura Group plc Business Overview
- 4.5.3 Vectura Group plc Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Vectura Group plc Pulmonary Hypertension Drug Product Portfolio
- 4.5.5 Vectura Group plc Recent Developments
- 4.6 Vicore Pharma AB
- 4.6.1 Vicore Pharma AB Company Information
- 4.6.2 Vicore Pharma AB Business Overview
- 4.6.3 Vicore Pharma AB Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Vicore Pharma AB Pulmonary Hypertension Drug Product Portfolio
- 4.6.5 Vicore Pharma AB Recent Developments
- 4.7 Bayer AG
- 4.7.1 Bayer AG Company Information
- 4.7.2 Bayer AG Business Overview
- 4.7.3 Bayer AG Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Bayer AG Pulmonary Hypertension Drug Product Portfolio
- 4.7.5 Bayer AG Recent Developments
- 4.8 Sanofi
- 4.8.1 Sanofi Company Information
- 4.8.2 Sanofi Business Overview
- 4.8.3 Sanofi Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Sanofi Pulmonary Hypertension Drug Product Portfolio
- 4.8.5 Sanofi Recent Developments
5 Global Pulmonary Hypertension Drug Market Scenario by Region
- 5.1 Global Pulmonary Hypertension Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Pulmonary Hypertension Drug Sales by Region: 2021-2032
- 5.2.1 Global Pulmonary Hypertension Drug Sales by Region: 2021-2026
- 5.2.2 Global Pulmonary Hypertension Drug Sales by Region: 2027-2032
- 5.3 Global Pulmonary Hypertension Drug Revenue by Region: 2021-2032
- 5.3.1 Global Pulmonary Hypertension Drug Revenue by Region: 2021-2026
- 5.3.2 Global Pulmonary Hypertension Drug Revenue by Region: 2027-2032
- 5.4 North America Pulmonary Hypertension Drug Market Facts & Figures by Country
- 5.4.1 North America Pulmonary Hypertension Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Pulmonary Hypertension Drug Sales by Country (2021-2032)
- 5.4.3 North America Pulmonary Hypertension Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Pulmonary Hypertension Drug Market Facts & Figures by Country
- 5.5.1 Europe Pulmonary Hypertension Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Pulmonary Hypertension Drug Sales by Country (2021-2032)
- 5.5.3 Europe Pulmonary Hypertension Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Pulmonary Hypertension Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Pulmonary Hypertension Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Pulmonary Hypertension Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Pulmonary Hypertension Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Pulmonary Hypertension Drug Market Facts & Figures by Country
- 5.7.1 South America Pulmonary Hypertension Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Pulmonary Hypertension Drug Sales by Country (2021-2032)
- 5.7.3 South America Pulmonary Hypertension Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Pulmonary Hypertension Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Pulmonary Hypertension Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Pulmonary Hypertension Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Pulmonary Hypertension Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Pulmonary Hypertension Drug Sales by Type (2021-2032)
- 6.1.1 Global Pulmonary Hypertension Drug Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Pulmonary Hypertension Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Pulmonary Hypertension Drug Revenue by Type (2021-2032)
- 6.2.1 Global Pulmonary Hypertension Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Pulmonary Hypertension Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Pulmonary Hypertension Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Pulmonary Hypertension Drug Sales by Application (2021-2032)
- 7.1.1 Global Pulmonary Hypertension Drug Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Pulmonary Hypertension Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Pulmonary Hypertension Drug Revenue by Application (2021-2032)
- 7.2.1 Global Pulmonary Hypertension Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Pulmonary Hypertension Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Pulmonary Hypertension Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Pulmonary Hypertension Drug Value Chain Analysis
- 8.1.1 Pulmonary Hypertension Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Pulmonary Hypertension Drug Production Mode & Process
- 8.2 Pulmonary Hypertension Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Pulmonary Hypertension Drug Distributors
- 8.2.3 Pulmonary Hypertension Drug Customers
9 Global Pulmonary Hypertension Drug Analyzing Market Dynamics
- 9.1 Pulmonary Hypertension Drug Industry Trends
- 9.2 Pulmonary Hypertension Drug Industry Drivers
- 9.3 Pulmonary Hypertension Drug Industry Opportunities and Challenges
- 9.4 Pulmonary Hypertension Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst